. Author manuscript; available in PMC: 2018 Oct 1.

Published in final edited form as: J Allergy Clin Immunol. 2017 May 10;140(4):933–949. doi: 10.1016/j.jaci.2017.04.024

Table 3.

Randomized controlled trials in primary prevention of asthma using HDM allergen avoidance

Studies	Year/s recruited	N	Assessments (Years)	Major findings
Isle of Wight (110–112)	1990	120	1, 2, 4, 8, 18	Reduced asthma and atopy at all ages 1–18
MAAPPS^*(109, 115, 116)	1995–1997	291	1, 3, 5, 8, 16	Reduced severe wheezing (infancy) Improved lung function (age 3 years) Increased mite sensitization (age 3 years)
CaPPS(113, 114, 149)	1995	545	1, 2, 7, 15	Reduced asthma (up to age 7 and at age 15 in females only)
PIAMA(118–120)	1996/97	810	1, 2, 3, 4, 5, 6, 7, 8	Reduced asthma at age 2. No effect at other ages.
CAPS(121)	1997–1999	616	18 mo., 3, 5	No difference in asthma, wheeze or atopy. Eczema higher in intervention group.

Published outcomes of the intervention in MAAPPS available for ages one and three years only